Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Genentech Herceptin Detailing Will Work To Limit Tykerb To Salvage Patients

  • News

Executive Summary

Genentech's counterdetailing efforts for Herceptin will focus on limiting use of GlaxoSmithKline's Tykerb to refractory advanced and metastatic breast cancer patients, Genentech BioOncology VP-Sales and Marketing John Orwin said Nov. 16

You may also be interested in...



GSK Tykerb Priced At Discount To Herceptin In Metastatic Breast Cancer

GlaxoSmithKline is pricing its breast cancer therapy Tykerb at a slight discount to Genentech's Herceptin (trastuzumab) in the metastatic breast cancer setting

GSK Tykerb Priced At Discount To Herceptin In Metastatic Breast Cancer

GlaxoSmithKline is pricing its breast cancer therapy Tykerb at a slight discount to Genentech's Herceptin (trastuzumab) in the metastatic breast cancer setting

Herceptin Adjuvant Approval Has 65% Higher Price Than Metastatic Therapy

The average cost per one-year course of Herceptin (trastuzumab) for adjuvant HER2-positive breast cancer will be $38,007, or 65% more than a course for the biologic's metastatic breast cancer indication

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Tags:
Latest Headlines

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

See All
UsernamePublicRestriction

Register

PS047786

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By